triple inhalation therapydupilumabchronic obstructive pulmonary diseaseCOPDtype 2 inflammationBOREASNCT03930732
…nflammation (screening blood eosinophil count ≥300 cells/mL) on triple inhalation therapy. Patients received dupilumab 300 mg every two weeks (q2w) or pl…